Why are Ansell shares on investors' radars today?

Management sees the deal growing sales and earnings.

| More on:
Health professional putting on gloves.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ansell Ltd (ASX: ANN) shares are in focus today after the company announced it finalised a major acquisition.

The purchase was made for all of the assets in US-listed entity Kimberly-Clark Corporation (NYSE: KMB)'s personal protective equipment (PPE) business – a deal Ansell initially announced on 8 April 2024.

Despite the completion of this major acquisition, Ansell shares remain steady at $25.90 per share at the time of writing, flat with the previous close of $25.91 apiece. Here's a closer look.

Ansell shares on radar after transaction

Kimberly-Clark is a US consumer goods giant, holding over 175 brands under its banner. Many are household names – Kleenex tissues and Huggies diapers are two examples.

It has a market capitalisation of US$47.8 billion at the time of writing.

The rationale behind the deal was to expand Ansell's product portfolio and market position. The $970 million transaction will see it acquire brands like Kimtech and KleenGuard – both used for anti-contamination against bacteria and viruses.

It also includes several manufacturing assets used in the production of gloves, masks, apparel, and eyewear.

Financial implications

The deal was finalised today after Ansell secured long-term debt financing to settle the balance.

It raised US$377 million via the United States Private Placement (USPP) market. The other portion of the deal was funded through a fully underwritten institutional placement of approximately 17.8 million new Ansell shares on 8 April, where it raised $400 million at $22.45 per share.

Since that date, these investors have made a 15% return on their money as I write.

The new debt facility announced today will replace previous instruments Ansell was using to fund its growth. As such, management noted this should provide Ansell with financial stability going into FY 2025:

The USPP proceeds replace the previously announced fully committed bridge facility which will no longer need to be drawn, with maturities on the notes issued ranging from 5 to 12 years and providing Ansell with long term funding certainty going into FY25.

Outlook for Ansell shares

Despite the size and potential impact of the acquisition, Ansell shares have not seen immediate movement in early trade on Tuesday.

Investors might be taking a wait-and-see approach, considering the complexities and integration efforts associated with such a significant purchase.

But analysts appear to be optimistic about the deal's long-term benefits. According to CommSec, Anshell shares are rated as a moderate buy, with 6 buy and 6 hold recommendations, respectively.

Ansell's management also expects the acquisition to be beneficial. It expects revenues and earnings per share (EPS) to grow directly as a result of the move. We will just have to wait and see if this is positive for Ansell shares or not.

The company's full-year results for FY 2024 are set to be released on 20 August, per the announcement.

In the last 12 months, Ansell shares have slipped over 4.5% into the red. This year to date, the stock has lifted into the green following a 6% return in the past month of trade.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Healthcare Shares

CSL shares: 'Healthy growth at a reasonable price'

Bell Potter thinks that investors should be buying this top stock before it's too late.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Why is this ASX 300 healthcare stock surging 12% today?

An announcement is getting investors excited today. Let's find out what's happening.

Read more »

Three health professionals at a hospital smile for the camera.
Share Gainers

Best 3 ASX 200 healthcare shares for price growth in FY24

In terms of share price gains, this trio of healthcare companies is in rude health.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

What happened with the CSL share price in FY 2024?

CSL shares didn’t shoot the lights out in 2024 but dividends hit record highs.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

Broker upgrades CSL shares to 'buy' — could they hit $335?

Another upgrade for the biotech giant.

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

Why the CSL share price could be 'undervalued' at $293

These experts say CSL shares are primed to shoot higher.

Read more »

A man in a wheelchair stretches both arms into the air in success.
Healthcare Shares

Top broker says Medibank shares could return 19% in FY25

This stock is predicted to produce healthy returns in FY25.

Read more »

Stressed thoughtful old female general practitioner doctor physician looking in distance, considering difficult medical problem solution or illness treatment, working on computer in clinic office.
Healthcare Shares

What's the outlook for ASX healthcare shares in FY25?

Could it be a healthy year?

Read more »